Disturbances in the endogenous cannabinoid (ECB) system in schizophrenia may contribute to their enhanced sensitivity to psychoactive substances, and the beneficial effects of second-generation antipsychotics for substance abuse in schizophrenia may involve modulatory effects on ECB. To verify these two assumptions, 29 patients (24 completers) with schizophrenia and substance use disorders (SUD) were treated with quetiapine for 12 weeks, and peripheral ECB levels were measured, using high-performance liquid chromatography/mass spectrometry, in patients (weeks 0, 6 and 12) and 17 healthy volunteers. Baseline anandamide levels were significantly higher in patients, relative to controls. This result is consistent with studies describing ECB dysfunctions in schizophrenia. SUD parameters improved during treatment, but no changes in ECB occurred over time. Improvements in substance abuse were probably not mediated by modulatory effects of quetiapine on ECB. Lastly, baseline anandamide predicted endpoint SUD scores (alcohol/ cannabis). Anandamide is a potential target for medications aimed at relieving SUD in schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0269881107083816 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Recurrence of psychosis after the surgical resection and radiation of a temporal lobe astrocytoma.
Front Psychiatry
January 2025
Department of Psychiatry and Behavioral Sciences, University of California, Davis Medical Center, Sacramento, CA, United States.
It is estimated that the incidence of first episode psychotic disorder is about 33 people out of 100,000 each year. Beyond primary psychotic illness (e.g.
View Article and Find Full Text PDFDespite 75% of people who experience a first episode of psychosis (FEP) reaching clinical remission, this population continue to face lower rates of vocational recovery. This review aimed to identify the factors which help and hinder individuals' employment and post-secondary education engagement post-FEP. Three electronic databases (Psych INFO, Medline and Social Science Database) were searched up to 21st August 2023.
View Article and Find Full Text PDFPredictive coding in neuropsychiatric disorders: a systematic transdiagnostic review.
Neurosci Biobehav Rev
January 2025
Department of Brain and Behavioral Sciences, University of Pavia, Italy. Electronic address:
The predictive coding framework postulates that the human brain continuously generates predictions about the environment, maximizing successes and minimizing failures based on prior experiences and beliefs. This PRISMA-compliant systematic review aims to comprehensively and transdiagnostically examine the differences in predictive coding between individuals with neuropsychiatric disorders and healthy controls. We included 72 case-control studies investigating predictive coding as the primary outcome and reporting behavioral, neuroimaging, or electrophysiological findings.
View Article and Find Full Text PDFPsychopathology trajectories and relapse in first episode schizophrenia with assured long-acting injectable adherence over 24 months.
Schizophr Res
January 2025
Faculty of Medicine and Health Sciences, Department of Psychiatry, Stellenbosch University, Tygerberg, 7500 Cape Town, South Africa.
Background: Relapse following a first episode of schizophrenia (FES) is common and often results in serious adverse psychosocial consequences. Treatment non-adherence is a key risk factor for relapse, but why relapse occurs despite antipsychotic treatment adherence remains unclear. This study examined the differences in FES psychopathology trajectories over 24-months with assured long-acting injectable antipsychotic (LAIA) treatment, to control for treatment adherence between those who relapsed and those who did not and what moderates these group differences.
View Article and Find Full Text PDFPartial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder.
Curr Neuropharmacol
January 2025
Clinic Villa Von Siebenthal, Rome, Italy.
Introduction/objective: Schizophrenia with substance use disorder is a complex clinical condition that may increase treatment resistance. Cannabis use disorder is frequently associated with psychosis and the causal link has still to be defined. Partial D2/3 agonists may ensure limbic dopamine release normalization while avoiding reduced frontocortical dopamine release, which would contribute to negative symptoms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!